| Bioactivity | SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0.6 μM (SARS-CoV nsp14)[1]. |
| Target | IC50: 0.6 ± 0.1 μM (SARS-CoV nsp14), 247.5 ± 14.9 μM (hRNMT) |
| Invitro | SARS-CoV-IN-4 (compound 13) shows inhibitory activity on N7-MTases, with inhibition at 50 μM of 97.2 ± 2.7% (SARS-CoV nsp14), and 33.9 ± 3.3% (hRNMT), respectively[1].SARS-CoV-IN-4 stabilizes SARS-CoV nsp14 against thermal denaturation with a ΔTm +10.8 °C and exhibits notable binding affinity (apparent KD 1.3 ± 0.87 μM)[1]. |
| Name | SARS-CoV-IN-4 |
| CAS | 2445585-37-3 |
| Formula | C28H31ClN12O11S |
| Molar Mass | 779.14 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ahmed-Belkacem R, et al. Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase. Eur J Med Chem. 2020 Sep 1;201:112557. |
SARS-CoV-IN-4
CAS: 2445585-37-3 F: C28H31ClN12O11S W: 779.14
SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.